Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03803150 Completed - Clinical trials for Facial Nerve Injuries

Evaluation of Preauricular Retromandibular Anteroparotid Versus Retromandibular Through Parotid Approach

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Of all the bones in the maxillofacial area, the condylar process is the most susceptible to fracture. The incidence of condylar fracture accounts for 25% to 50% of all mandibular fractures. Though remained controversial for a long time, surgical treatment of displaced subcondylar fractures appears today as the gold standard. Although there is a developing preference for open reduction and internal fixation of mandibular condylar fractures, the optimal approach to the ramus condylar unit remains controversial. Various approaches have been proposed, and each has specific shortcomings and disadvantages. Retromandibular, submandibular, transoral, and through parotid approaches are generally performed and sometimes used with an endoscope. Limited access and injury to the facial nerve are the most common problems, while Wilson introduced a new through masseter anteroparotid approach, this technique offers excellent access to the ramus condylar unit, and facial nerve damage risk is reduced.

NCT ID: NCT03803124 Completed - Clinical trials for Polycystic Kidney, Autosomal Dominant

Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD

POLY
Start date: December 2015
Phase: Phase 3
Study type: Interventional

Polycystic kidney disease (ADPKD) is a common genetic disorder, characterized by the formation of cysts in the kidneys, causing gradual renal function-loss. Previous studies have shown that, reduced glomerular filtration rate (GFR) and renal plasma flow (RPF) play a role in the progression of renal disease in ADPKD. Tolvaptan is a vasopressin 2 antagonist, which seems to reduce the growth of total kidney volume (TKV) and the decline in e-GFR in ADPKD. The mechanism is not fully understood and could, at least partly, be caused by stimulation of the renal blood flow. The purpose of this trial is to investigate if tolvaptan´s improve renal blood flow and glomerular filtration in ADPKD, in a randomized, cross-over, double-blind, placebo-controlled study.

NCT ID: NCT03802916 Completed - Clinical trials for Iron Overload Due to Repeated Red Blood Cell Transfusions

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

TWICE
Start date: March 6, 2019
Phase: Phase 2
Study type: Interventional

Safety, tolerability, and acceptability of twice-daily dosing with deferiprone delayed-release (DR) tablets in patients with systemic iron overload.

NCT ID: NCT03802591 Completed - Clinical trials for Gastric Adenocarcinoma

A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

Start date: March 28, 2019
Phase: Phase 3
Study type: Interventional

This is a phase III, multi-Center, randomized, placebo-controlled trial to investigate the efficacy and safety of CS1001 in combination with Oxaliplatin and Capecitabine (CAPOX) chemotherapy in first-line subjects with unresectable locally advanced or metastatic gastric adenocarcinoma (GC) or gastro-esophageal junction (GEJ) adenocarcinoma.

NCT ID: NCT03802396 Completed - Clinical trials for Postoperative Delirium

Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction

MARBLE
Start date: July 15, 2018
Phase: Phase 2
Study type: Interventional

This research study will evaluate the effectiveness and estimate the feasibility of administering an investigational drug called 'CN-105' (the study drug), to prevent postoperative cognitive decline, delirium (serious confusion) and underlying brain inflammatory and brain activity changes in adults 60 years and older undergoing surgery.

NCT ID: NCT03802279 Completed - Clinical trials for Rhabdomyolysis Linked to a Hereditary Disease of Metabolism

Evaluate the Effort Test as a Therapeutic Monitoring Tool in Acute Rhabdomyolyses

EFFORHAB
Start date: October 25, 2019
Phase:
Study type: Observational

The prognosis of rhabdomyolyses related to hereditary diseases of metabolism is poor and treatments are only symptomatic. Rhabdomyolysis outbreaks are frequently precipitated by fever and fasting. They are unpredictable. In spite of the care of patient in an intensive care unit, the occurrence of renal failure and heart rhythm disorders explains a significant acute-phase mortality rate. There is an urgent need to understand the pathophysiological mechanisms of rhabdomyolyses related to hereditary diseases of metabolism, in order to identify specific treatments. Patients with rhabdomyolyses have few clinical signs outside of access. So there is a methodological difficulty in following a treatment test. There is an urgency to identify follow-up parameters in anticipation of new therapies. The objective of this study is to validate the hypothesis that effort test and cardiac function parameters are usable in the treatment monitoring for patients with acute rhabdomyolysis linked to a hereditary disease of metabolism and thus propose the effort test as an assessment tool for future clinical trials. In order to do so, the correlation between the results of the effort tests, performed to each patient with rhabdomyolysis related to a hereditary disease of metabolism, with the severity of the disease will be evaluated. This study is original because it opens up innovative prospects for monitoring in the field of hereditary diseases of metabolism, with the identification of new monitoring tools.

NCT ID: NCT03802240 Completed - Clinical trials for Non-Squamous Non-Small Cell Lung Cancer

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Start date: July 11, 2019
Phase: Phase 3
Study type: Interventional

The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients will be investigated in this clinical trial.

NCT ID: NCT03802097 Completed - Gastric Cancer Clinical Trials

Study About no Antimicrobial Prophylaxis in Totally Laparoscopic Distal Gastrectomy

KSWEET-03
Start date: December 27, 2018
Phase: N/A
Study type: Interventional

Laparoscopic gastrectomy has fewer infectious complications compared to open surgery. Recently, the incidence of postoperative infectious complications was greatly reduced due to the development of surgical techniques and improvement of prevention and control of surgical infection. Previous multicenter, phase II study (KSWEET-01) revealed that the incidence of infectious complications of laparoscopic gastrectomy without prophylactic antibiotics was not significantly higher than previously reported data. Therefore, this study aim to prove the safety of totally laparoscopic distal gastrectomy without prophylactic antibiotics, specially reference to the postoperative infectious complications.

NCT ID: NCT03801382 Completed - Clinical trials for Cognitive Functioning of Healthy Individuals

Psychometric Properties of IntelliSpace Cognition

Start date: April 15, 2019
Phase: N/A
Study type: Interventional

This study aims to validate the tests that are on the IntelliSpace Cognition platform and to establish normative data for these tests.

NCT ID: NCT03801317 Completed - Stunting Clinical Trials

The Effect of Bovine Colostrum/ Egg Supplementation in Young Malawian Children

Start date: December 3, 2018
Phase: N/A
Study type: Interventional

The trial will consist of adding either a supplement of 4.3g egg powder + 5.7g bovine colostrum or a control flour along with a multiple micronutrient powder to the diets of healthy Malawian children 9 months of age. This supplement provides additional essential amino acids, choline and immunoactive colostrum. Children will be receive either the supplement or control for 12 weeks. Children will have regular follow-up where anthropometry is measured. At enrollment and after 12 weeks, stool will be collected and a urinary lactulose permeability test conducted. Children will be measured at enrollment and at weeks 2, 4, 8, 12, 20, 32 after enrollment.